Download chapter (PDF 452kb)
Chapter at a glance
- We have sought to design a
mechanism to which industry will
respond by increasing R&D on
vaccines for diseases occurring
mainly in developing countries.
- Industry is attracted to the
concept of payment for results;
the market mechanism fits
their business model well and
preserves the role of intellectual
property rights and market sales
financing commercial investment in
pharmaceutical R&D.
- Our consultations revealed a range
of priorities for the commitment
from different parts of industry.
- An advance market commitment
would be of value to developingcountry
suppliers, which often do
not benefit from other incentive
arrangements.
- Complementary measures
are needed to improve the
procurement of existing vaccines,
improve demand forecasts and
increase funding for existing drugs
and vaccines.
Read full chapter (PDF 452kb)
|